1. Home
  2. SLDB vs NKTR Comparison

SLDB vs NKTR Comparison

Compare SLDB & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLDB
  • NKTR
  • Stock Information
  • Founded
  • SLDB 2013
  • NKTR 1990
  • Country
  • SLDB United States
  • NKTR United States
  • Employees
  • SLDB N/A
  • NKTR N/A
  • Industry
  • SLDB Biotechnology: Biological Products (No Diagnostic Substances)
  • NKTR Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLDB Health Care
  • NKTR Health Care
  • Exchange
  • SLDB Nasdaq
  • NKTR Nasdaq
  • Market Cap
  • SLDB 227.3M
  • NKTR 247.9M
  • IPO Year
  • SLDB 2018
  • NKTR 1994
  • Fundamental
  • Price
  • SLDB $4.03
  • NKTR $0.94
  • Analyst Decision
  • SLDB Strong Buy
  • NKTR Buy
  • Analyst Count
  • SLDB 11
  • NKTR 3
  • Target Price
  • SLDB $17.91
  • NKTR $4.00
  • AVG Volume (30 Days)
  • SLDB 279.8K
  • NKTR 2.2M
  • Earning Date
  • SLDB 11-06-2024
  • NKTR 11-07-2024
  • Dividend Yield
  • SLDB N/A
  • NKTR N/A
  • EPS Growth
  • SLDB N/A
  • NKTR N/A
  • EPS
  • SLDB N/A
  • NKTR N/A
  • Revenue
  • SLDB N/A
  • NKTR $93,137,000.00
  • Revenue This Year
  • SLDB N/A
  • NKTR $12.85
  • Revenue Next Year
  • SLDB N/A
  • NKTR N/A
  • P/E Ratio
  • SLDB N/A
  • NKTR N/A
  • Revenue Growth
  • SLDB N/A
  • NKTR 5.53
  • 52 Week Low
  • SLDB $4.05
  • NKTR $0.46
  • 52 Week High
  • SLDB $15.05
  • NKTR $1.93
  • Technical
  • Relative Strength Index (RSI)
  • SLDB 29.01
  • NKTR 41.05
  • Support Level
  • SLDB $4.82
  • NKTR $0.99
  • Resistance Level
  • SLDB $5.40
  • NKTR $1.05
  • Average True Range (ATR)
  • SLDB 0.34
  • NKTR 0.06
  • MACD
  • SLDB -0.08
  • NKTR 0.01
  • Stochastic Oscillator
  • SLDB 1.63
  • NKTR 22.92

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Share on Social Networks: